We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+2.85%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$14.8B
AUM Growth
+$2.92B
(+25%)
Cap. Flow
+$3.28B
Cap. Flow
% of AUM
22.14%
Top 10 Holdings %
Top 10 Hldgs %
12.56%
Holding
1,029
New
443
Increased
269
Reduced
185
Closed
112
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$217M |
| 2 |
Apple
AAPL
|
+$208M |
| 3 |
Microsoft
MSFT
|
+$199M |
| 4 |
Amazon
AMZN
|
+$136M |
| 5 |
Arthur J. Gallagher & Co
AJG
|
+$133M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$125M |
| 2 |
Gilead Sciences
GILD
|
+$107M |
| 3 |
PR
Permian Resources
PR
|
+$85.4M |
| 4 |
Reddit
RDDT
|
+$84.1M |
| 5 |
Keysight
KEYS
|
+$79M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.96% |
| 2 | Technology | 25.64% |
| 3 | Financials | 7.58% |
| 4 | Industrials | 6.88% |
| 5 | Communication Services | 6.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
MoonLake Immunotherapeutics
MLTX
$1.49B
| $15.9M | 0.11% |
293,535
+61,105
| +26% | +$3.12M |
|
252
Arrowhead Research
ARWR
$12.2B
| $15.8M | 0.11% |
840,174
-25,620
| -3% | -$528K |
|
253
Core & Main
CNM
$8.71B
| $15.8M | 0.11% |
310,014
+121,538
| +64% | +$5.73M |
|
254
Mettler-Toledo International
MTD
$28.5B
| $15.7M | 0.11% |
12,832
-15,805
| -55% | -$20.6M |
|
255
nVent Electric
NVT
$26.2B
| $15.7M | 0.11% |
+229,609
| New | +$16.9M |
|
256
Viridian Therapeutics
VRDN
$2.33B
| $15.6M | 0.11% |
813,647
-5,348
| -0.7% | -$116K |
|
257
Curtiss-Wright
CW
$27.6B
| $15.5M | 0.1% |
43,698
+6,084
| +16% | +$2.19M |
|
|
WBTN
258
WEBTOON Entertainment Inc
WBTN
$1.26B
| $15.5M | 0.1% |
1,140,800
| – | – |
|
259
STAG Industrial
STAG
$7.19B
| $15.4M | 0.1% |
+456,700
| New | +$16.7M |
|
|
VRE
260
DELISTED
Veris Residential
VRE
| $15.3M | 0.1% |
922,515
+353,540
| +62% | +$6.17M |
|
261
Supernus Pharmaceuticals
SUPN
$2.73B
| $15.3M | 0.1% |
423,828
+235,257
| +125% | +$8.28M |
|
262
Toll Brothers
TOL
$14.5B
| $15.3M | 0.1% |
+121,284
| New | +$18M |
|
263
IDEAYA Biosciences
IDYA
$3.47B
| $15.2M | 0.1% |
590,697
+1,943
| +0.3% | +$55K |
|
264
Check Point Software Technologies
CHKP
$12.8B
| $15.2M | 0.1% |
+81,217
| New | +$15.3M |
|
265
Edgewise Therapeutics
EWTX
$4.84B
| $15.1M | 0.1% |
567,218
+39,379
| +7% | +$1.25M |
|
266
Monster Beverage
MNST
$92.4B
| $14.8M | 0.1% |
281,316
-30,626
| -10% | -$1.62M |
|
267
Chevron
CVX
$371B
| $14.5M | 0.1% |
+100,368
| New | +$15.4M |
|
268
Viatris
VTRS
$20.6B
| $14.5M | 0.1% |
1,165,542
+272,128
| +30% | +$3.34M |
|
269
Coca-Cola
KO
$374B
| $14.5M | 0.1% |
+232,831
| New | +$15.2M |
|
270
Immatics
IMTX
$1.34B
| $14.5M | 0.1% |
2,034,224
-467,738
| -19% | -$4.02M |
|
271
Trip.com Group
TCOM
$28.9B
| $14.5M | 0.1% |
210,634
-103,420
| -33% | -$6.84M |
|
|
CRGX
272
DELISTED
CARGO Therapeutics
CRGX
| $14.4M | 0.1% |
1,001,134
-10,341
| -1% | -$188K |
|
273
Humacyte
HUMA
$197M
| $14.4M | 0.1% |
2,848,802
+2,000,268
| +236% | +$9.9M |
|
274
Texas Roadhouse
TXRH
$13.7B
| $14.4M | 0.1% |
79,612
+6,266
| +9% | +$1.18M |
|
|
ALTM
275
DELISTED
Arcadium Lithium plc
ALTM
| $14.4M | 0.1% |
+2,800,000
| New | +$14.3M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q4 2024 Portfolio in Review
As of Q4 2024, Woodline Partners held 1,029 positions worth $14.8B, up 25% from $11.9B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Woodline Partners deployed $3.28B of net new capital in Q4 2024, opening 443 new positions and adding to 269 existing holdings. Its largest new stake was TE Connectivity: 890,754 shares worth $127M.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 43% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Gilead Sciences, an estimated $107M trimmed.
- Woodline Partners's largest Q4 2024 buy was TE Connectivity: 890,754 shares worth $127M.
- Woodline Partners added most to NVIDIA in Q4 2024, an estimated $217M increase.
- Woodline Partners's biggest Q4 2024 reduction was Gilead Sciences, cutting an estimated $107M.
- Woodline Partners fully exited ASML in Q4 2024, selling an estimated $125M.
- Woodline Partners's ten largest holdings make up 13% of its $14.8B portfolio in Q4 2024.
- Woodline Partners opened 443 new positions and closed 112 in Q4 2024.
- Woodline Partners's portfolio value rose 25% quarter-over-quarter to $14.8B.
Based on Woodline Partners's 13F filing for Q4 2024, filed 14 Feb 2025.